Big, revolutionary, vertical deals to change structure of health industry are dramatic but tough to pull off. Will CVS PBM customers worry about funding a competitor?

Amgen gets into RNAi for cardiovascular indications with Arrowhead deal. Lilly and J&J out-license preclinical candidates, for epilepsy and cancer respectively, to smaller firms Cerecor and Tracon.

Investors looking to benefit from growth in the health care provision sector are circling as major Australian hospital operator Healthscope considers a relisting or potential trade sale.